Rapid RT-PCR identification of SARS-CoV-2 in screening donors of fecal microbiota transplantation.
Fecal microbiota transplantation (FMT)
Performance evaluation
RT-PCR
STANDARD™ M10 SARS-CoV-2
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
24
04
2023
revised:
22
05
2023
accepted:
16
06
2023
medline:
27
6
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Since its first appearance in late 2019 in Wuhan, China, severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2) has had a major impact on healthcare facilities around the world. Although in the past year, mass vaccination and the development of monoclonal antibody treatments have reduced the number of deaths and severe cases, the circulation of SARS-CoV-2 remains high. Over the past two years, diagnostics have played a crucial role in virus containment both in health care facilities and at the community level. For SARS-CoV-2 detection, the commonly used specimen type is the nasopharyngeal swab, although the virus can be identified in other matrices such as feces. Since fecal microbiota transplantation (FMT) assumes significant importance in the treatment of chronic gut infections and that feces may be a potential vehicle for transmission of SARS-CoV-2, in this study we have evaluated the performance of the rapid cartridge-based RT-PCR test STANDARD™ M10 SARS-CoV-2 (SD Biosensor Inc., Suwon, South Korea) using fecal samples. The results obtained indicates that STANDARD™ M10 SARS-CoV-2 can detect SARS-CoV-2 in stool samples even at low concentration. For this reason, STANDARD™ M10 SARS-CoV-2 could be used as reliable methods for the detection of SARS-CoV-2 in fecal samples and for the screening of FMT donors.
Identifiants
pubmed: 37366528
doi: 10.1016/j.heliyon.2023.e17438
pii: S2405-8440(23)04646-7
pmc: PMC10277158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e17438Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
BMC Microbiol. 2021 Feb 19;21(1):56
pubmed: 33607939
Mayo Clin Proc. 2021 Jun;96(6):1418-1425
pubmed: 34088413
Access Microbiol. 2022 May 20;4(5):acmi000366
pubmed: 36003360
J Clin Med. 2022 Apr 27;11(9):
pubmed: 35566591
Microorganisms. 2022 Jan 26;10(2):
pubmed: 35208740
Int J Infect Dis. 2020 Jun;95:363-370
pubmed: 32335340
Lancet Respir Med. 2020 Apr;8(4):e18
pubmed: 32145829
Mol Biotechnol. 2004 Feb;26(2):133-46
pubmed: 14764939
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
J Clin Microbiol. 2001 Feb;39(2):485-93
pubmed: 11158094
J Appl Microbiol. 2012 Nov;113(5):1014-26
pubmed: 22747964
Clin Transl Gastroenterol. 2021 Jun 9;12(6):e00363
pubmed: 34106090
Front Microbiol. 2022 Nov 03;13:999783
pubmed: 36406396
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):642-643
pubmed: 32333844
J Clin Med. 2020 May 15;9(5):
pubmed: 32429101
Int J Infect Dis. 2020 Apr;93:264-267
pubmed: 32114193
J Clin Microbiol. 1992 Dec;30(12):3195-9
pubmed: 1452702
Clin Infect Dis. 2017 Aug 1;65(3):364-370
pubmed: 28369341
BMC Microbiol. 2021 Sep 6;21(1):242
pubmed: 34488633
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32611796
Dig Liver Dis. 2020 Dec;52(12):1390-1395
pubmed: 33004295
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):531
pubmed: 32240618
J Clin Virol. 2009 Mar;44(3):211-4
pubmed: 19196549
Cureus. 2022 Aug 25;14(8):e28402
pubmed: 36168377
Respiration. 2020;99(11):970-978
pubmed: 33075793
J Med Virol. 2021 Sep;93(9):5333-5338
pubmed: 33851739